Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Intellia Therapeutics (NTLA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Intellia Therapeutics (NTLA – Research Report) with bullish sentiments.

Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $450.00. The company’s shares closed last Friday at $416.50, close to its 52-week high of $418.71.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.2% and a 52.2% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Bristol-Myers Squibb, and Morphic Holding.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $395.22 average price target, representing a -4.8% downside. In a report issued on January 4, Argus Research also maintained a Buy rating on the stock with a $420.00 price target.

See today’s best-performing stocks on TipRanks >>

Intellia Therapeutics (NTLA)

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics yesterday and set a price target of $62.00. The company’s shares closed last Friday at $28.63.

According to TipRanks.com, Biliouris is a 3-star analyst with an average return of 2.2% and a 54.4% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Centessa Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $79.60, a 176.1% upside from current levels. In a report issued on January 4, Bank of America Securities also maintained a Buy rating on the stock with a $80.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VRTX:

• Entrada Therapeutics initiated with an Outperform at Oppenheimer
• William Blair biotech analysts to hold an analyst/industry conference call
• Vertex Pharmaceuticals named 2024 Top Pick at Argus
• The biopharmaceuticals stocks to own in 2024, according to BofA
• The Smid-cap biotech stocks to own in 2024, according to Bernstein